Data & Analytics
Pharmacovigilance Software Overview
Comprehensive Guide to FAERS Data
Guide to GVP Module IX
The RxView Blog
3 Thoughts on the 2019 DIA-PVRMS Conference
Top 5 Blog Posts in 2018
Videos - The Evolution of Pharmacovigilance Software
The Evolution of Pharmacovigilance Software
Quality Requirements in GVP Module IX for Signal Management
Signal Prioritization and Assessment in GVP Module IX for Signal Management
Signal Validation in GVP Module IX for Signal Management
The Signal Detection Process in GVP Module IX for Signal Management
An Introduction to GVP Module IX for Signal Management
A New Option for Safety Signal Management and Pharmacovigilance Workflow
Are Social Media Data used in Pharmacovigilance Biased?
Reducing the Noise from Social Media for Pharmacovigilance
What's Driving Pharmacovigilance Technology Acquisition?
The Value and Validity of Social Media Monitoring in Pharmacovigilance
Depression as a Drug Side-Effect: A Quick FAERS Analysis
Can Modern Analytics be Forced into Traditional Pharmacovigilance Workflow Tools?
Advera Health's Commitment to FAERS Data Quality and Turn Around Time
Social Media Monitoring for Pharmacovigilance and Drug Safety
2018- The Year of Next Gen Drug Safety and Pharmacovigilance 2.0
Top Free Drug Safety Downloads of 2017
Most Popular Drug Safety Articles of 2017
Analysis of a FDA Safety Signal: DPP-4's and Rhabdomyolysis
Evidex Goes Global - VigiBase Drug Safety Data Access
An Analysis of Adverse Events Associated with Endothelin Receptor Antagonists (ERAs) using FAERS
Santa Rosa Wildfires - A Very Tough Week at Advera Health
FAERS Thee Well - Drug Safety Excitement with FDA Dashboard
Dear FDA, There is No Single Truth Standard
How Pharmacovigilance Departments Can Work Smarter, Act Bigger
Case Studies: Signal Detection Utilizing FDA Adverse Event Reporting System (FAERS) Data
What happens when a Safety Signal contradicts Clinical Trial data?
FDA Releases Q1 2017 Drug Safety Watch List: It’s Boring and That’s Good
Canada’s March Toward Mandatory Reporting of Adverse Events by Providers
Happy (Drug Safety Data) Independence Day
Failure to Warn: The Week in Drug Safety News
How is Evidex Different from Traditional Signal Detection Software?
Post-Marketing Drug Safety and Pharmacovigilance Is Now More Important Than Ever
Pharmacovigilance 2.0 – Let Freedom Ring in Philadelphia!
2016 FDA Adverse Event Reporting System (FAERS) Data: An Infographic
Evidex Alerts After 3 Months: What We’ve Learned
Using FAERS to Determine Medical Costs – a Payer Perspective
Calculating the Reporting Rate of Adverse Events in FAERS – A New Methodology
Efficacy vs. Effectiveness - The Role of Pharmacovigilance
ICER Underestimates Adverse Event Rates and Costs for Multiple Sclerosis Medications
Make Hair Great Again - The Real Reason for FDA Reform
A Big Data Stumble in Healthcare
Increasing Pressure for Increased Pharmacovgilance Capabilities
Using FAERS Data and Clinical Evidence to Compare HER2+ Antagonists
Drug Safety Progressives – The Rise of the Pharmacovigilante
Advera Health Partners with APCER Life Sciences to Connect Drug Safety to Health Outcomes
Real-Time Drug Safety Analysis with Evidex Alerts
Will 2017 Be The Year of Drug Safety?
Working Toward a Cure: The Foundation for Sarcoidosis Research
Top 10 Free Report Downloads of 2016
Top 10 Advera Health Blog Posts of 2016
Looking Ahead - Drug Safety in 2017
How Memorial Hermann Uses an Evidence Aggregation Platform
Mitigating Drug Litigation Risk with an Evidence Aggregation Platform
Use Clinical Trial Results Linked to Real World Data for Better Formulary Reviews
When Things Go Right in Healthcare
A Drug Safety Data Point That No One Knows About
Establish Adverse Event Benchmarks with a Drug Safety Data Aggregation Platform
Why Does Adverse Event Reporting to FAERS Continue to Accelerate?
Uncover Hidden Data Points with a Drug Safety Data Aggregation Platform
How HEOR Can Demonstrate Cost Burden of Drug Adverse Events
Monitoring Biosimilars with a Drug Safety Data Aggregation Platform
HHS Says they are Finally Going to Enforce Clinical Trial Reporting. Will Anything Really Change?
Construct More Accurate Drug Forecasts using Clinical Trial Results and Real World Data
Seeing the Competitive Landscape with Clinical Trial Results Linked to Real World Data
Drug Safety Snail Mail. Really?
What is a Drug Safety Data Aggregation Platform?
The Drug Pricing Battle Wages On
How Information on Health Care’s Value is Currently Shared
Express Scripts’ 2017 Exclusions – Analysis Using Real World Data
Summer Slowdown? No, Summer Build!
Safety Score & Cost Burden Analysis Update – Which Drugs have Riskiest Profiles?
Guest Post: BBK Talks #BigData with Advera Health Analytics
Chronic Underreporting of Clinical Trials
Honest Salespeople Aren’t Dead
How to Make Sense of the ADA Conference Data Deluge
The Circus is in Town
Nothing is a Waste of Time
3 Reasons a Clinical Evidence Database for Multiple Sclerosis is Important
Playing the Long Game
The Comparative Safety of Multiple Sclerosis Medications – A 2016 Update
Show Me The Evidence!!!
Connect with Advera Health at the AMCP 2016 Annual Meeting
Payers Need Better Access to Clinical Trial Results Prior to Drug Approval
FDA’s Early Warning System is Broken
How Far We’ve Come
Evidex Use Case: Analysis of DPP-4 Inhibitors
How Will You Review All 60 drugs up for Approval in 2016?
A Crystal Ball for FDA Action: How we Validated RxSignal
Watson Health is the Ultimate Data Parasite
In Defense of Millennials
5 Steps to Forming a Consensus to Mitigate Adverse Events
A Quest for Evidence
Fear of Lost Privacy Costs Lives
The Long Run
It’s Confirmed: FDA is Failing When it Comes to Drug Safety
#JPM16 Talks Drug Pricing – Bad Idea!
Big Data, Technology, and the New Health Economy
Data Is Everything… Or Is It? Why Data Management Matters
Top 10 Free Report Downloads of 2015
Top 10 RxView Blog Posts of 2015
Mad as Hell and Not Going to Take This Anymore
Could Diabetes Patients’ Safety Been Improved if the SGLT2 – Ketoacidosis Link Were Known Sooner?
JMCP Validates the Ability to Quantify the Safety Risk of Drugs
Lack of Transparency is Disturbing, Unsurprising, and Validating
FDA is Slow so We FOIA
The Viekira Pak Effect – Will it Change P&T Practices for Good?
To Dare Is To Do
Abbvie’s Viekira Pak Costs $6.5 Million a Year in Avoidable Costs, Puts Patients at Greater Risk
Missing the Boat on the Drug Pricing Argument
The Right Data, Analytics And Measurements
What’s In a Name….Introducing Advera Health Analytics
RxSignal 3.0 - Predicting FDA Label Changes
The FDA Is Approving Everything – Is that Safe?
Choosing the Right Real World Drug Data
CVS Exclusion Decision May Put Patients at Risk on Diabetes Drug (SGLT-2’s)
Did Express Scripts Just Save the Healthcare System an Additional $107.8 Million?
Why is Everyone So Surprised about FDA Side Effect Reporting Delays?
900,000 Side Effect Reports That You Have Never Seen
The State of Drug Safety Systems
Drug Safety Advocate Call to Action
Let YOUR Voice Be Heard on Healthcare Improvement
It Is Time For A Change
When Opportunity Knocks, Open the Door
The Best Thing to Happen to Drug Safety (and it’s Free if you are Qualified)
Define Performance -- Pay-for-Performance Deals Can’t Leave Drug Safety Out
Predicting the Future? Yes, we can.
Shadow Pricing, Highway Robbery, and the Price of Drugs
A New Era of Drug Safety
The Non-Negotiable Cost of Drugs
Drug Safety Bandits
Trimming The Fat Off Of Post-Marketing Drug Safety
The Cost of Drug Safety
Monitoring the Safety of Biosimilars by Managed Care Organizations: A Practical Approach
An Indecent (Drug Safety) Proposal
Pharma’s Gonna Hate, and We Just Shake it Off
Drug Safety Perspectives on Hepatitis C
RxOutcome – A New Paradigm in Drug Safety
A Drug Safety Call to Arms
Will 2015 Really Be the Year of Healthcare Technology?
Hepatitis C Payer Scorecard: According to Peers, Express Scripts DID Make the Wrong Decision
Did Express Scripts Choose the Right Hepatitis C Drug?
Express Scripts and CVS Exclusivity Deals: Immediate Cost Savings Overshadow Long-Term Medical Concerns
10 Free Report Downloads to Start off the New Year!
2014: The year of data minions, drug safety hipsters, and scarface
Holy @#*!, I Didn’t Know that Drug Safety Data was Available!
3 Ways to Increase Adverse Event Reporting
Is the Status Quo Killing Healthcare?
Should Adverse Drug Event Reporting by Healthcare Providers be Mandatory?
Musings from 38,000 Feet
Data, Disproportionality, & Drug Safety Communications
Moneyball for Drug Safety
Chantix: Why the Black Box Warning Should Remain
Help! There are too many FDA Label Changes and Boxed Warnings and I Don’t Know Which Ones to Pay Attention To!
FAERS - Myths vs. Realities
3 Drug Safety Pharmacy Hacks to Identifying Drug Induced Conditions
Is it Vacation Time Yet?
The Apple iPhone Announcement: It is Only The Second Most Exciting Product Release This Week
How New-Agers and Hipsters are Popularizing Drug Safety
Post Approval Adverse Events... What's the Real World Impact? [INFOGRAPHIC]
Applying Broken Windows Policing Theory to Drug Safety
How Can You Tell When a Lawyer Is Lying?
August: Now The Scariest Month of the Year for Pharma Companies
Quiz: What Type of Drug Safety Professional Are You?
How many links does it take to get to the center of an FDA FOIA request?
OpenFDA – the Good, the Bad, and the Ugly
Why is Questcor’s Disclosure on Acthar Side Effects News?
Drug Safety World Cup: who will win it all?
Drug Safety World Cup: QuarterFinals
Drug Safety World Cup: Time for the Knockout Round!
Did You Know the World Cup has Started?
Hepatitis C: why side effects of treatment are a particularly big deal
3 Ways Drug Safety is Like Car Sales in the 1980’s
Taking A Break from Drug Safety – Honoring our Wounded Warriors this Memorial Day Weekend
From Drug Safety Advocate to Chief Product Officer
My Mother: Mom, Patient Advocate, and now Blogger
What does the FDA and Scarface Have in Common? They Both Understand Power
4 Conclusions on the Comparative Safety of Diabetes Drugs
A Framework for Comparable Drug Safety Research
The Big Reveal
FDA Releases Updated Drug Safety Data – Announces OpenFDA… Now hold your applause
Broad Research Study Published in DRUG SAFETY Refutes the ‘Weber Effect'
Qsymia and Belviq Obesity Drugs: When 'Approach Them Cautiously' Just Does Not Cut It
Logic. Math. Software. Drug Safety?
Highly Educated and Underutilized: Pharmacists Need to Be More Involved in Drug Safety
Does Brilinta Really Have a Better Drug Safety Profile Than Plavix?
Changing of the Guard - Redefining Drug Safety by Making Big Data Actionable & Predictable
5 Ways Pharmacists Can Better Communicate with Prescribers
Reported Drug Side Effects Have Resulted in 1.1 Million Hospitalizations
Happy New Year!
Wall Street Journal Puts "Me-Too" Drugs in Spotlight
Where Do Doctors Get Their Safety Information?
Why Are We Prescribing the ADHD Medications with the Most Dangerous Safety Profiles?
Did One Little Sentence Just Change Drug Safety Forever?
How Are Post-Approval Adverse Drug Event Data Obtained?
Howard Stern and a “Crappy” Patient Questionnaire
The Disconnect Between Clinical Trials and Real-World Side Effects
The FDA Should Look Closer at These 5 Drugs
The Myth of Alert Fatigue... Some Alerts Just Aren't Actionable!
Imagine a world where drug safety decisions could be made before a FDA Safety Alert
Did Express Scripts Make the Right Formulary Exclusions?
Why is Express Scripts Decision to Remove Drugs From Its Formulary News?
The New York Times Misses The Mark on High Cost of Asthma Inhalers
Patient Engagement, Innovation, and ROI
Can Psychotic Side Effects be Triggered by the Drugs My Child is Taking for ADHD?
3 More Philadelphia Eagle Lessons for Healthcare Leadership
When the FDA approves a drug, that means it is safe, right?
I’m Not Only the Executive Vice President of AdverseEvents, I’m Also a Patient
In The Beginning…FDA Created a Data Nightmare
5 Lessons Drug Safety Can Learn from the NFL
Evidence Based Medicine Without Access to All of the Evidence
Without ROI, Big Data in Healthcare is Doomed
427 Mendocino Avenue, Suite 150, Santa Rosa California 95401
Copyright 2019 | Advera Health Analytics, Inc.